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Summary 
Evaluation of the Human Research Act (HRA) that has been in force since 2014 
The Human Research Act (HRA) and its associated ordinances have been in force since 2014. Next to 
its primary aim of protecting human beings in research, it also aims at ensuring the quality and trans-
parency of research involving human beings as well as creating favourable conditions for such research. 
In federal Switzerland, cantonal ethics committees (ECs) are responsible for authorising human re-
search projects (HRPs). Depending on the type of the project, approval of the Swiss Agency for Thera-
peutic Products (Swissmedic) or the Federal Office of Public Health (FOPH) may also be required.  
In order to assess the effectiveness of the newly introduced HRA and to identify potential for improve-
ment, the FOPH has commissioned the Department of Political Science at the University of Zurich (IPZ) 
and KEK-CDC Consultants to evaluate the HRA. The evaluation of the HRA relies on diverse methods 
and integrates the perspectives of the different stakeholders in research involving human beings. It also 
set out to analyse the quality of research activities subject to the HRA. Due to time constraints and the 
complexity of this analysis, it had to be separated from the evaluation.  
Analysis of the quality of selected human research projects (HRPs) by external specialists 
The exploratory analysis of the quality of HRPs focuses on 13 selected projects that have been submitted 
to the EC in 2016. Its aim is to obtain qualitative assessments of the diverse research activities subject 
to the HRA. This is why HRPs from the eight most frequent study types and all seven ECs were ana-
lysed. Consequently, the HRPs analysed are subject to the Clinical Trials Ordinance (ClinO) or the Hu-
man Research Ordinance (HRO). Dealing with diverse research topics, the HRPs analysed were mostly 
initiated by the investigators, but the analysis also covers HRPs initiated by the industry or third parties. 
It needs to be considered that in 2016, when the HRPs analysed were submitted, a part of the imple-
mentation activities of the HRA were still in the process of establishing and improving.i 
In order to ensure a systematic assessment, we developed human research quality criteria on the basis 
of the Swiss regulations, international guidelines, literature and a discussion with the evaluation’s ad-
visory group. The human research quality criteria consist of total eight criteria that are assigned to 
either a scientific or an ethical dimension. All criteria need to be considered to assess the risks, burdens 
and benefits associated with an HRP.  
We commissioned four external specialists based outside of Switzerland to assess the quality of the 
individual HRPs selected with respect to the human research quality criteria. The external specialists’ 
assessments are based on the electronic dossiers at the ECs and, if applicable, Swissmedic. Among other 
documents, the dossiers most importantly contain the study protocol and participant information, but 
also the authorities’ decision letters. The analysis is limited to the authorization procedure until initial 
approval of the analysed HRPs. Given the sensitivity of the data analysed, the results are solely pre-
sented in the form of an overarching synthesis of the individual assessments of the quality of the HRPs. 
Largely positive assessment of the HRPs’ quality with a few concerns related to the research design 
Overall, the analysis shows that the external specialists assess the quality of the 13 selected HRPs 
largely positive. Regarding most of the analysed HRPs, the external specialists have no or only minor 
 
i For more information about the implementation activities, see the evaluation of the HRA:  
Widmer, Thomas/ Frey, Kathrin/ Eberli, Daniela/ Schläpfer, Basil/ Rickenbacher, Julia (2019): Evaluation of the Human Research Act 
(HRA). Executive Summary. Zurich: Department of Political Science at the University of Zurich and KEK-CDC Consultants. 
Widmer, Thomas/ Frey, Kathrin/ Eberli, Daniela/ Schläpfer, Basil/ Rickenbacher, Julia (2019): Evaluation des Humanforschungsge-
setzes (HFG). Schlussbericht. Zürich: Institut für Politikwissenschaft der Universität Zürich und KEK-CDC Consultants. 
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concerns with respect to one or few criteria. Most often, the external specialists miss information about 
the (planned) analyses, and they question whether the HRPs will yield reliable results. They also find 
that the criteria for selecting participants are not always comprehensively documented or that they are 
too strictly defined. In a few cases, the external specialists miss information about the division of tasks 
within the HRP. The results further tend to indicate that the documentation primarily contains expla-
nations about planned scientific publications, whereas there is no information on how study partici-
pants are to be informed about the study results. Only in single cases, the external specialists have 
considerable concerns about an HRP. These concerns mostly relate to major shortcomings in the re-
search design, and partly connected to this, the principal investigators’ limited expertise in clinical re-
search.  
Higher quality of the HRPs initiated by the industry, no differences between study types 
Given that 13 HRPs were analysed, we can only make tentative inferences about differences between 
the HRPs. Generally, the external specialists assess the quality of industry-initiated or international 
HRPs more positively than the quality of investigator-initiated HRPs. This result is supported by pre-
vious government research on the completeness and accuracy of randomized controlled clinical trial 
study protocols submitted to Swiss ECs in 2012 and 2016.ii Furthermore, even though HRPs subject to 
the ClinO mostly required approval already prior to the HRA, we observe a few but no systematic 
differences between the assessments of the quality of HRPs subject to the HRO and the assessments of 
HRPs subject to the ClinO. One notable difference is that the external specialists only had concerns 
about the relevance of the research question for HRPs subject to the HRO.  
The analysis further confirms the overall positive assessment of the authorities’ decisions and their 
focus on the protection and information of the participants. The external specialists find the ECs’ and 
Swissmedic’s decisions largely to be comprehensible and well founded. In line with the legal frame-
work, Swissmedic’s comments on the five HRPs that were subject to its approval focused largely on 
the quality and safety of the therapeutic products used. Regarding the EC, whose authorization was 
necessary in all the 13 HRPs, the external specialists often describe the comments as fully appropriate 
or very helpful. However, the external specialists also point to concerns that they have but which are 
not reflected in the ECs’ comments. These concerns refer to the suitability of the research design, the 
selection criteria and, in one case, the further use of data or material without gathering informed con-
sent of the persons concerned.  
Focus on scientific aspects of quality complementary to previous results 
Therefore, the results of the analysis of the quality of selected HRPs provide additional insights to the 
evaluation of the HRA and government research by drawing the attention to the scientific dimension 
of human research quality. The external specialists expressed still few, but relatively many concerns 
about criteria of the scientific dimension compared to the criteria of the ethical dimension. The evalua-
tion of the HRA and government research rather highlight the ethical dimension because they clearly 
indicate a need for improving the information of participants and the transparency of research involv-
ing human beings. Still, the present analysis’ emphasis on the scientific dimension does not contradict 
previous results. Rather, the external specialists with an academic background and somewhat circum-
stantial knowledge of the Swiss regulations may have focused more on scientific aspects. Overall, this 
analysis thus reveals exploratory findings about the quality of research activities within the HRA and 
complements approaches and findings of the evaluation of the HRA and government research projects.   
 
ii For the reports of all the government research projects mentioned, see: https://www.bag.admin.ch/bag/en/home/das-bag/ressort-
forschung-evaluation/forschung-im-bag/forschung-biomedizin/ressortforschungsprojekte-humanforschung.html [as at 19.12.2019]. 
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Zusammenfassung 
Evaluation des schweizerischen Humanforschungsgesetzes (HFG), das seit 2014 in Kraft ist 
Das Humanforschungsgesetz (HFG) und die dazugehörigen Verordnungen sind seit 2014 in Kraft. Ne-
ben dem primären Zweck des Schutzes des Menschen in der Forschung beabsichtigt das HFG auch, 
günstige Rahmenbedingungen für die Humanforschung zu schaffen und deren Qualität und Transpa-
renz zu gewährleisten. In der föderalistischen Schweiz sind die kantonalen Ethikkommissionen (EK) 
verantwortlich für die Bewilligung aller Humanforschungsprojekte (HFP). Je nach Art des HFP bedarf 
es einer zusätzlichen Bewilligung des Schweizerischen Heilmittelinstituts (Swissmedic) oder des Bun-
desamts für Gesundheit (BAG).  
Um die Wirksamkeit des neu erlassenen HFG zu überprüfen und allfälligen Optimierungsbedarf zu 
identifizieren, beauftragte das BAG das Institut für Politikwissenschaft der Universität Zürich (IPZ) 
und KEK-CDC Consultants mit der Evaluation des HFG. Gestützt auf diverse Methoden berücksichtigt 
die Evaluation die verschiedenen Sichtweisen der Beteiligten an der Humanforschung. Ein Ziel der 
Evaluation war, die Qualität der gemäss HFG bewilligungspflichtigen Forschungsaktivitäten zu ana-
lysieren. Aufgrund zeitlicher Einschränkungen und der Komplexität dieser Analyse musste sie aus der 
Evaluation des HFG ausgelagert werden. 
Analyse der Qualität ausgewählter Humanforschungsprojekte (HFP) durch externe Fachpersonen  
Die explorative Analyse der Qualität von HFP konzentriert sich auf 13 ausgewählte Projekte, die 2016 
bei den EK eingereicht wurden. Ziel der Analyse ist es, qualitative Einschätzungen der vielfältigen 
Forschungsaktivitäten im Rahmen des HFG zu erhalten. Daher wurden HFP aus allen sieben EK und 
den acht häufigsten Studientypen analysiert. Entsprechend sind die untersuchten HFP in der Verord-
nung über klinische Versuche (KlinV) oder der Humanforschungsverordnung (HFV) geregelt und be-
fassen sich mit diversen Themen. Die meisten der untersuchten HFP wurden von den Prüfpersonen 
initiiert, die Analyse umfasst aber auch von der Industrie oder Dritten initiierte HFP. Es ist zu beachten, 
dass die untersuchten HFP 2016 eingereicht worden sind, als sich die Umsetzungsaktivitäten zum HFG 
teilweise erst etablierten und einspielten.iii 
Anhand der Rechtsgrundlagen, internationalen Richtlinien, Literatur und einer Diskussion mit der Be-
gleitgruppe der Evaluation haben wir Qualitätskriterien der Humanforschung entwickelt, die eine sys-
tematische Beurteilung erlauben. Die Qualitätskriterien umfassen insgesamt acht Kriterien, die entwe-
der einer wissenschaftlichen oder einer ethischen Dimension zugeordnet sind. Alle Kriterien müssen 
berücksichtigt werden, um die Risiken, Belastungen und Nutzen eines HFP abzuwägen. 
Wir haben vier externe Fachpersonen, die nicht in der Schweiz ansässig sind, mit der Analyse der Qua-
lität der ausgewählten HFP anhand der Qualitätskriterien beauftragt. Die externen Fachpersonen be-
werteten die Qualität der einzelnen 13 HFP auf Basis der bei den EK und, falls zutreffend, Swissmedic 
elektronisch verfügbaren Dossiers. Unter anderem beinhalten diese Dossiers namentlich den Studien-
plan, die Information zuhanden der Forschungsteilnehmenden und die Entscheide der Behörden. Die 
Analyse ist auf das Verfahren bis zur erstmaligen Bewilligung beschränkt. Aufgrund der Vertraulich-
keit der analysierten Daten werden die Resultate in Form einer übergreifenden Synthese der Qualitäts-
analysen der einzelnen HFP präsentiert. 
 
iii Siehe die Evaluation des HFG für mehr Informationen zu den Umsetzungsaktivitäten: 
Widmer, Thomas/ Frey, Kathrin/ Eberli, Daniela/ Schläpfer, Basil/ Rickenbacher, Julia (2019): Evaluation des Humanforschungsge-
setzes (HFG). Executive Summary. Zürich: Institut für Politikwissenschaft der Universität Zürich und KEK-CDC Consultants. 
Widmer, Thomas/ Frey, Kathrin/ Eberli, Daniela/ Schläpfer, Basil/ Rickenbacher, Julia (2019): Evaluation des Humanforschungsge-
setzes (HFG). Schlussbericht. Zürich: Institut für Politikwissenschaft der Universität Zürich und KEK-CDC Consultants. 
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Grösstenteils positive Beurteilung der Qualität der HFP, wenige Bedenken zum Forschungsdesign 
Insgesamt zeigt die Analyse, dass die externen Fachpersonen die Qualität der 13 ausgewählten HFP 
überwiegend positiv bewerten. Die externen Fachpersonen äussern bei den meisten der analysierten 
HFP keine oder nur geringe Bedenken zu einem oder wenigen Qualitätskriterien. Am häufigsten fehlen 
ihnen Angaben zu den (geplanten) Analysen oder sie stellen in Frage, ob das HFP belastbare Resultate 
hervorbringen wird. Zudem bemerken sie, dass die Kriterien zur Auswahl der Forschungsteilnehmen-
den nicht immer nachvollziehbar oder zu strikt definiert sind. In wenigen Fällen fehlen den externen 
Fachpersonen Angaben über die Arbeitsaufteilung im HFP. Weiter weisen die Resultate tendenziell 
darauf hin, dass die Unterlagen vor allem Aufschluss über geplante wissenschaftliche Publikationen 
geben, während Angaben dazu fehlen, wie Forschungsteilnehmende über die Studienergebnisse infor-
miert werden. Nur in einzelnen Fällen äussern die externen Fachpersonen schliesslich wesentliche Be-
denken zu einem HFP. Anlass dazu geben erhebliche Schwächen im Forschungsdesign, und teilweise 
damit verbunden, mangelnde Expertise der Prüfpersonen in klinischer Forschung.   
Industrie-initiierte HFP mit besser bewerteter Qualität, keine Unterschiede nach Studientyp 
Zumal 13 HFP analysiert worden sind, können wir nur bedingt Schlüsse über Unterschiede zwischen 
den HFP ziehen. Generell schätzen die externen Fachpersonen die Qualität von Industrie-initiierten 
oder internationalen HFP deutlich positiver ein als die Qualität von Prüfperson-initiierten HFP. Dieses 
Ergebnis wird gestützt durch die Ressortforschung zur Vollständigkeit und Genauigkeit von Studien-
protokollen für randomisierte kontrollierte klinische Versuche, die 2012 und 2016 bei den Schweizer 
EK eingereicht worden sind.iv Weiter beobachten wir keine systematischen Unterschiede zwischen den 
Bewertungen der Qualität der HFP im Bereich der HFV und der KlinV, obschon HFP im Bereich der 
KlinV zumeist bereits vor Einführung des HFG eine Bewilligung benötigten. Ein bemerkenswerter Un-
terschied ist aber, dass die externen Fachpersonen die Relevanz der Forschungsfrage nur bei HFP im 
Bereich der HFV kritisch bewerten. 
Die Analyse bestätigt weiter die insgesamt positive Beurteilung der Entscheide der Behörden und ihr 
Fokus auf den Schutz und die Aufklärung der Forschungsteilnehmenden. Die externen Fachpersonen 
bewerten die Entscheide von EK und Swissmedic überwiegend als verständlich und fundiert. In Über-
einstimmung mit den Rechtsgrundlagen konzentrierte sich Swissmedic bei den fünf von ihr genehmig-
ten HFP vor allem auf die Qualität und Sicherheit der verwendeten Heilmittel. Die Ausführungen der 
EK, die alle 13 HFP bewilligen mussten, bezeichnen die externen Fachpersonen häufig als angemessen 
oder sehr hilfreich. Sie weisen jedoch auch darauf hin, dass gewisse ihrer Bedenken nicht in den Aus-
führungen der EK aufgegriffen werden. Dabei geht es um Fragen zur Eignung des Forschungsdesigns, 
zu den Auswahlkriterien der Forschungsteilnehmenden und in einem Fall zur Weiterverwendung von 
bereits gewonnenen Daten oder Material mit Verzicht auf eine Einwilligung der betroffenen Personen. 
Fokus auf wissenschaftlichen Aspekten der Qualität ergänzend zu bisherigen Ergebnissen 
Die Ergebnisse der Analyse der Qualität ausgewählter HFP lenken folglich die Aufmerksamkeit auf 
die wissenschaftliche Dimension der Qualität von Humanforschung und erweitern damit die Ergeb-
nisse der Evaluation des HFG und der Ressortforschung. Die externen Fachpersonen haben zwar we-
nige aber doch relativ häufiger Bedenken zu Qualitätskriterien der wissenschaftlichen Dimension ge-
äussert als zu jenen der ethischen Dimension. Die Evaluation des HFG und die Ressortforschung beto-
nen hingegen die ethische Dimension, indem sie klaren Verbesserungsbedarf bei der Information und 
Aufklärung der Forschungsteilnehmenden und der Transparenz der Humanforschung aufzeigen. Dass 
 
iv Für die Berichte aller genannten Ressortforschungsprojekte siehe: https://www.bag.admin.ch/bag/de/home/das-bag/ressortfor-
schung-evaluation/forschung-im-bag/forschung-biomedizin/ressortforschungsprojekte-humanforschung.html [Stand 19.12.2019].  
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die wissenschaftliche Dimension in der vorliegenden Analyse kritischer diskutiert wird, widerspricht 
aber nicht den bisherigen Ergebnissen. Eher haben wahrscheinlich die externen Fachpersonen mit ei-
nem wissenschaftlichen Hintergrund und begrenzten Kenntnissen der schweizerischen Regelung stär-
ker auf wissenschaftliche Aspekte fokussiert. Insgesamt gibt die vorliegende Analyse erste Einblicke in 
die Qualität der Forschungsaktivitäten im Rahmen des HFG und ergänzt damit die bisherigen Ansätze 
und Ergebnisse der Ressortforschungsprojekte und der Evaluation des HFG.   
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Résumé 
Évaluation de la loi relative à la recherche sur l’être humain (LRH) en vigueur depuis 2014 
La loi fédérale relative à la recherche sur l’être humain (LRH), assortie de ses ordonnances d’exécution, 
est en vigueur depuis 2014. En plus de son but primaire de protéger les êtres humains dans le cadre de 
la recherche, la loi vise également à assurer la qualité et la transparence de la recherche sur l’être hu-
main et à aménager des conditions favorables pour des telles recherches. Dans la structure fédéraliste 
de la Suisse, les commissions cantonales d’éthique (CE) sont compétentes pour octroyer les autorisa-
tions pour des projets de recherche sur l’être humain (PRH). En fonction du type de projet, une autori-
sation délivrée par l’Institut suisse des produits thérapeutiques (Swissmedic) ou par l’Office fédéral de 
la santé publique (OFSP) peut aussi être exigée. 
Afin d’examiner l’efficacité de la nouvelle LRH et d’identifier les potentiels d’optimisation, l’OFSP a 
chargé l’Institut de science politique de l’Université de Zurich (IPZ) et KEK-CDC Consultants d’évaluer 
la LRH. L’évaluation de la LRH s’appuie sur plusieurs méthodes et prend en compte les perspectives 
des différentes parties prenantes à la recherche sur l’être humain. L’évaluation avait également pour 
but d’analyser la qualité des activités de recherche soumises à autorisation en vertu de la LRH. En 
raison des contraintes temporelles et de la complexité de cette analyse, elle a dû être séparée de l’éva-
luation.  
Analyse de la qualité d’une sélection de projets de recherche sur l’être humain (PRH) par des experts 
externes  
L’analyse de la qualité des PRH exploratoire porte sur 13 projets sélectionnés qui ont été soumis aux 
CE en 2016. Elle a pour objectif d’obtenir des appréciations qualitatives des activités de recherche va-
riées qui s’inscrivent dans le cadre de la LRH. C’est pourquoi la sélection des PRH analysés prend en 
considération l’entièreté des sept CE et les huit types d’études les plus fréquents. En conséquence, les 
PRH analysés sont soumis à l’ordonnance sur les essais cliniques (OClin) ou à l’ordonnance relative à 
la recherche sur l’être humain (ORH). Traitant de divers sujets, les PRH analysés ont surtout été initiés 
par les investigateurs, mais l’analyse couvre également des PRH initiés par l’industrie ou par des tiers. 
Il faut tenir compte du fait qu’en 2016, lorsque les PRH analysés ont été soumis, une partie des activités 
de mise en œuvre de la LRH n’étaient pas encore complètement établies et éprouvées.v 
Afin d’assurer une appréciation systématique, nous avons développé des critères de qualité de la re-
cherche sur l’être humain en nous basant sur la réglementation suisse, les directives internationales, la 
littérature et une discussion avec le groupe d’accompagnement de l’évaluation de la LRH. Les critères 
de qualité de la recherche sur l’être humain comprennent huit critères au total qui sont attribués soit à 
une dimension scientifique, soit à une dimension éthique. Tous les critères doivent être pris en compte 
pour juger des risques, des contraintes et des bénéfices associés à un PRH.  
Nous avons mandaté quatre experts externes résidant à l’étranger pour analyser la qualité des diffé-
rents PRH sélectionnés en fonction des critères de qualité de la recherche sur l’être humain. Les analyses 
des experts externes sont basées sur les dossiers électroniques disponibles auprès des CE et, le cas 
échéant, de Swissmedic. Ces dossiers contiennent, entre autres documents, le protocole d’étude et les 
 
v Pour de plus amples informations sur les activités de mise en œuvre de la LRH, voir l’évaluation de la LRH: 
Widmer, Thomas/ Frey, Kathrin/ Eberli, Daniela/ Schläpfer, Basil/ Rickenbacher, Julia (2019): Évaluation de la loi relative à la re-
cherche sur l’être humain (LRH). Executive Summary. Zurich: Institut de science politique de l’Université de Zurich et KEK-CDC Con-
sultants. 
Widmer, Thomas/ Frey, Kathrin/ Eberli, Daniela/ Schläpfer, Basil/ Rickenbacher, Julia (2019): Evaluation des Humanforschungsge-
setzes (HFG). Schlussbericht. Zürich: Institut für Politikwissenschaft der Universität Zürich und KEK-CDC Consultants. 
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informations destinées aux participants à la recherche, mais aussi les décisions des autorités. L’analyse 
se limite à la procédure jusqu’à l’autorisation initiale des PRH analysés. Compte tenu de la confiden-
tialité des données analysées, les résultats ne sont présentés que sous la forme d’une synthèse globale 
des analyses individuelles des 13 PRH. 
Bilan largement positif de la qualité des PRH, avec quelques réserves quant au design de recherche 
Dans l’ensemble, l’analyse montre que les experts externes portent une appréciation largement positive 
sur la qualité des 13 PRH sélectionnés. Pour la plupart des PRH analysés, les spécialistes externes ont 
exprimé peu ou pas de réserve quant à un ou quelques critères de qualité. Le plus souvent, les experts 
externes manquent d’informations sur les analyses (planifiées) et se demandent si les PRH produiront 
des résultats fiables. Ils constatent également que les critères de sélection des participants à la recherche 
ne sont pas toujours documentés de manière exhaustive ou qu’ils sont trop strictement définis. Dans 
quelques cas, les experts externes manquent d’informations sur la répartition des tâches au sein du 
PRH. Les résultats tendent en outre à indiquer que la documentation contient essentiellement des pré-
cisions sur les publications scientifiques planifiées, alors que les informations sur la manière dont les 
participants à la recherche seront informés des résultats de l’étude ne sont pas disponibles. Les experts 
externes n’ont formulé des réserves sérieuses au sujet d’un PRH que dans des cas singuliers. Ces ré-
serves sont principalement liées à des faiblesses considérables dans le design de recherche et, en partie 
au manque connexe d’expertise des investigateurs en recherche clinique. 
Meilleure qualité des PRH initiés par l’industrie, aucune différence entre les types d’études 
Étant donné que 13 PRH ont été analysés, nous ne pouvons que tirer des conclusions limitées sur les 
différences entre les PRH. En général, les experts externes donnent une appréciation nettement plus 
positive de la qualité des PRH initiés par l’industrie ou des PRH internationaux que de celle des PRH 
initiés par les investigateurs. Ce résultat est corroboré par des recherches sectorielles sur l’exhaustivité 
et l’exactitude des protocoles d’essais cliniques contrôlés randomisés soumis aux CE suisses en 2012 et 
2016.vi De plus, même si une autorisation était déjà exigée avant la LRH pour la plupart des études 
relevant du champ d’application de la ClinO, nous n’observons pas de différences systématiques entre 
les appréciations de la qualité des PRH soumis à la OClin et celles des PRH soumis à la ORH. Une 
différence notable réside en revanche dans le fait que les experts externes ne se sont préoccupés que de 
la pertinence de la question de recherche pour les PRH soumis à l’ORH.  
L’analyse confirme en outre le jugement globalement positif des décisions des autorités et l’accent mis 
sur la protection et l’information des participants par les autorités. Les experts externes estiment que 
les décisions des CE et de Swissmedic sont largement compréhensibles et fondées. Conformément aux 
bases légales, les remarques de Swissmedic à propos des cinq PRH dans sa responsabilité ont porté 
essentiellement sur la qualité et la sécurité des produits thérapeutiques utilisés. Les commentaires des 
CE, qui ont dû autoriser les 13 PRH, sont souvent décrits par les experts externes comme appropriés 
ou très utiles. Toutefois, les experts externes soulignent également que certaines de leurs réserves ne 
sont pas reflétées dans les commentaires des CE. Celles-ci portent sur la pertinence du design de re-
cherche, les critères de sélection des participants à la recherche et, dans un cas, la réutilisation de don-
nées ou d’échantillons sans le consentement préalable des personnes concernées.  
 
 
 
vi Les rapports sur tous les projets de recherche sectorielle mentionnés, voir : https://www.bag.admin.ch/bag/fr/home/das-bag/res-
sortforschung-evaluation/forschung-im-bag/forschung-biomedizin/ressortforschungsprojekte-humanforschung.html [état au 
1.4.2019]. 
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L’accent mis sur des aspects scientifiques de la qualité complète les résultats existants  
Les résultats de l’analyse de la qualité des PRH sélectionnés attirent par conséquent l’attention sur la 
dimension scientifique de la qualité de la recherche sur l’être humain et permettent ainsi d’élargir les 
résultats de l’évaluation de la LRH et de la recherche sectorielle. Les experts externes ont exprimé peu 
de réserves sur la qualité des PRH. Cependant, les réserves émises étaient relativement plus fréquentes 
sur les critères de la dimension scientifique que sur les critères de la dimension éthique. L’évaluation 
de la LRH et la recherche sectorielle soulignent quant à elles plutôt la dimension éthique car elles indi-
quent clairement la nécessité d’améliorer l’information des participants à la recherche et la transparence 
de la recherche sur l’être humain. Même si les résultats de l’analyse mettent l’accent sur la dimension 
scientifique, ils ne sont pas contradictoires aux résultats existants. Les experts externes, avec leur par-
cours académique et professionnel et des connaissances limités de la réglementation suisse, ont proba-
blement focalisé leurs appréciations sur des aspects scientifiques. En somme, la présente analyse offre 
un premier regard sur la qualité des activités de recherche soumises à la LRH et complète les approches 
et résultats de l’évaluation de la LRH et des projets de recherche sectorielle. 
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1 Introduction 
1.1 Human Research Act (HRA): Swiss regulation of research involving humans 
In Switzerland, research on diseases and on the structure and function of the human body is regulated 
in the Federal Act on Research involving Human Beings (Human Research Act, HRA; SR 810.30). As 
specified in Art. 1 of the HRA, its primary purpose is “to protect the dignity, privacy, and health of 
humans being involved in research”. Secondary purposes are to create favourable conditions for re-
search involving humans and to contribute to ensuring the quality and transparency of such research. 
Detailed provisions for the implementation of the HRA are specified in the Ordinance on Clinical Trials 
in Human Research (ClinO; SR 810.305), the Ordinance on Human Research with the Exception of Clin-
ical Trials (HRO; SR 810.301), and the Ordinance on Organisational Aspects of the Human Research 
Act (OrgO-HRA; SR 810.308).  
The HRA and its associated ordinances have been in force since 1 January 2014 and brought several 
key innovations: 
- Introduction of a nationwide regulation of research involving humans. 
- Extension of the scope of research involving humans that requires authorization: In addition to 
clinical trials, which had mostly already been regulated, research with non-anonymized biological 
or gene material and research with health-related personal data also requires authorization. 
- Introduction of the risk-adapted approach, which implies that the provisions for authorization 
and reporting differ depending on the risks and burdens associated with the research activities 
planned. The risk is indicated by three categories ranging from A (lowest) to C (highest). 
- Clarification of the responsibilities of the authorities responsible for approving research involving 
humans, introduction of the lead procedure for ethics committees in the case of multicentre studies, 
determination of processing deadlines for the authorities. 
The HRA is implemented at several levels in federal Switzerland. The cantonal ethics committees (ECs) 
are responsible for the approval of every human research project (HRP). While each canton needs to 
designate an EC, the cantons can also appoint a common EC. Currently, seven cantonal ECs exist. The 
ECs have founded a joint association called swissethics.  
Depending on the type and risk of the HRP, an additional approval or a statement from a national 
authority is required. Clinical trials with medicinal products or medical devices entailing an elevated 
risk also require the approval of the Swiss Agency for Therapeutic Products (Swissmedic). Clinical tri-
als of transplantation need also to be approved by the Federal Office of Public Health (FOPH).1 The 
FOPH further manages the Coordination Office for Human Research (kofam) that aims at ensuring the 
exchange of the involved authorities and at informing the public about the Swiss regulation on research 
involving humans. 
1.2 Evaluation of the HRA and analysis of the quality of selected human research projects (HRPs) 
Based on the evaluation clause in Art. 61 of the HRA, the FOPH has commissioned the Department of 
Political Science at the University of Zurich (IPZ) and KEK-CDC Consultants to evaluate the HRA. The 
evaluation addresses the following four main questions:  
1) How is the human research regulation being implemented? 
 
1 The Swiss Expert Committee for Biosafety (SECB), the Federal Office of Environment (FOEN) and the FOPH are further involved in 
authorization procedures by writing statements. 
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2) Is the HRA achieving the desired effects as stated in the article defining the purpose of the HRA 
(Art. 1)? Are there unintended effects (positive, negative, possible interactions)? 
3) Which context factors influence the implementation of the HRA?  
4) How can the human research regulation and its implementation be improved? 
In order to take the different perspectives of the actors involved in the HRA into account, the evaluation 
used several methods and sources (see Table A 1 in the Appendix). On the one hand, we conducted 
interviews, surveys and workshops with the diverse stakeholders involved and we employed extensive 
document analyses and secondary data analyses. On the other hand, we relied on government research 
projects that were commissioned by the FOPH and aimed at investigating specific aspects of the HRA. 
Feedback of the evaluation’s FOPH in-house steering group and an advisory group has been integrated 
continuously in evaluation conduct and reporting. The evaluation took place between August 2017 and 
June 2019. The final evaluation report was submitted in Mid-August 2019 (Widmer et al. 2019a)2. 
Next to other relevant aspects, the evaluation of the HRA also aimed at analysing the quality of research 
activities that are subject to the HRA. For this purpose, we commissioned external specialists to assess 
the quality of 13 selected HRPs on the basis of the application dossiers submitted to the authorities and 
the corresponding decision letters of the authorities. For their assessment, the external specialists relied 
on human research quality criteria that we developed. Because of the complexity of this endeavour and 
the diverse actors involved, it soon became apparent that it is not possible to conduct the analysis 
within the timeframe planned for the evaluation of the HRA.3 This is why the analysis of the quality of 
selected HRPs is presented this separate report. 
The objective of the present analysis is to provide qualitative information about the applications for 
authorization of HRPs and the decisions made by the authorities. It thus speaks to the evaluation ques-
tions on the implementation of the HRA and its effects, namely on how the HRA ensures the quality of 
research involving human beings as stated in its Art. 1 (questions no. 1 and 2). It is not the objective of 
the present analysis to compare the external specialists’ assessments of the quality of the selected HRPs 
with the respective decisions of the authorities, namely the ECs. The ECs are responsible for assessing 
whether HRPs and the conduct thereof meet the ethical, legal and scientific requirements stipulated in 
the HRA. In particular, the ECs are responsible for assessing whether the protection of the persons 
concerned is guaranteed (Art. 51 HRA). Therefore, the ECs prioritize ethical to scientific considerations 
and aim at integrating multiple disciplines to comprehensively assess the risks and benefits of an HRP 
(swissethics 2013; Widmer et al. 2019a: 27). The external specialists, on the other hand, were commis-
sioned to assess the extent to which the selected HRPs fulfil the human research quality criteria. Lastly, 
because Swissmedic is responsible for reviewing the safety and quality of the therapeutic product used, 
comparisons between Swissmedic’s and the external specialists’ assessments seem less evident.4 
1.3 Outline of the report at hand 
This report adds to the evaluation of the HRA and presents the analysis of the quality of selected HRPs. 
Following these introductory remarks, Chapter 2 outlines the methodical approach of the analysis. 
Chapter 3 explains the quality criteria used for the analysis. Chapter 4 presents and discusses the main 
results, which are based on a synthesis of the analyses of quality of the individual HRPs conducted by 
four external specialists. Chapter 5 summarizes purpose, background and main results of the analysis.   
 
2 The main report has been written in German. English and French translations of the executive summary are available. 
3 Detailed information about the diverse steps needed to conduct the present analysis are outlined in Chapter 2.  
4 Swissmedic’s tasks are stipulated in Art. 32 ClinO and the Therapeutic Products Act (SR 812.21), incl. its ordinances.   
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2 Methods and approach 
Several tasks were necessary to conduct the analysis of the quality of selected HRPs. First, we selected 
the HRPs to be analysed and gained permission to access the electronic documentation of the selected 
HRPs’ application dossiers. In parallel, we developed human research quality criteria as a conceptual 
framework for the analysis. Afterwards, we commissioned external specialists to provide individual 
assessments of the quality of the selected HRPs. Lastly, we synthesized the results of the individual 
reports. The following sections describe these steps in detail and discuss limitations of our approach. 
2.1 Case selection of the HRPs and description of the selected HRPs 
After consultation with the FOPH, we initially selected 18 approved HRPs to be analysed.5 The selec-
tion aims at covering the diversity of study types of research involving humans requiring authorization 
according to the HRA and its associated ordinances. Therefore, two HRPs each were selected from the 
nine most frequent study types. Applications from all seven ECs were selected.6 For the respective EC, 
study types were selected with which it deals relatively frequently both in comparison with its number 
of other applications and in comparison with other ECs’ number of applications. The objective of this 
approach is to select (fairly) typical cases of an EC. The single HRPs within one study type and EC have 
then been selected at random from all HRPs submitted to all the ECs in 2016 that eventually received 
approval. This allowed choosing HRPs that were, at the time, in the process of being conducted or had 
already been completed. 
Due to amendments in the course of the work, the present analysis effectively covers 13 of the 18 ini-
tially selected HRPs.7 On the one hand, the researchers involved8 in three HRPs did not give their con-
sent for the external specialists to access the application documentation. On the other hand, an external 
analysis of two HRPs was not feasible because of their language and topic. Table 1 illustrates the case 
selection by giving an overview of all applications approved in 2016 per study type and EC. One HRP 
was selected within every cell shaded in grey. The present analysis focuses on the HRPs in the cells 
shaded in dark grey. Table 1 thus shows that although the number of the analysed HRPs had to be 
reduced, the present analysis still covers all seven ECs and eight of the nine most frequent study types.  
 
5 We first proposed to also select three HRPs that the authorities rejected. However, the ECs did not agree with this proposition. HRPs 
that have been rejected or withdrawn were later integrated in the evaluation by means of interviews with applicants of such HRPs. 
6 At first, six ECs agreed to the analysis of the research quality of selected HRPs with the seventh EC only later agreeing to the analysis. 
As we had contacted researchers of the selected HRPs in the meantime, minor adaptations to the initial selection were needed.  
7 As a part of the evaluation of the HRA, interviews with the applicants of all the 18 HRPs were conducted. The interviews aimed at 
assessing the applicant’s perception of the authorization procedure concerning the specific HRP as well as generally, see Chapter 4 in 
the evaluation report (Widmer et al. 2019a: 39-49). 
8 We use the term “researchers involved” as an umbrella term that comprehends principal investigators (ClinO), project leaders (HRO), 
sponsors, applicants or third parties involved.  
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Table 1: Number of applications submitted and approved in 2016 per EC and selected HRPs 
  Applications submitted and approved in 2016 
  
Total Zurich 
North 
Central 
Switzer-
land 
Vaud Bern Geneva 
Eastern 
Switzer-
land 
Ticino 
Clinical trials of medicinal products, 
transplant products (TpP), gene ther-
apy (GT) or pathogenic/ genetically 
modified organisms (GMO) 
222 54 54 25 41 14 16 18 
 Category A medicinal products 24 3 4 4 7 2 4 - 
 Category B medicinal products 54 10 17 6 11 5 1 4 
 Category C medicinal products 141 40 33 14 23 6 11 14 
 Category C TpP 3 1 - 1 - 1 - 0 
 Category C GT / GMO 0 - - - 0 - - - 
Clinical trials of medical devices  45 21 8 22 11 7 4 
 Category A 88 32 16 6 15 9 6 4 
 Category C 30 13 5 2 7 2 1 - 
Other clinical trials  44 37 19 22 23 11 9 
 Category A 146 39 33 18 17 21 10 8 
 Category B 19 4 4 1 5 2 1 1 
HRP besides clinical trials  384 306 299 202 157 49 35 
 Including persons, category A 625 125 137 148 85 86 25 19 
 Including persons, category B 21 7 5 4 2 3 - - 
 Further use of health-related data 
and/or biological material 
766 248 158 145 114 62 24 16 
 Including deceased 18 4 7 2 - 5 - - 
 Including embryos & foetuses 2 - - - 1 1 - - 
Total 1937 527 418 351 287 205 83 66 
         
 1 application selected; analysis conducted  1 application selected; analysis not feasible 
Source: The data are excerpted from BASEC, received from swissethics on 30 October 2017.  
- : no applications submitted / 0 : at least 1 application submitted, but no applications with a final decision of “approved”.  
Not included in the table because no applications existed within Switzerland in 2016: Clinical trials of TpP or GT/GMO in category A or 
B, clinical trials of transplantation. 
 
Table 2 further presents main characteristics of the 13 HRPs selected for the present analysis. It shows 
that about three quarters of the selected HRPs was initiated by the investigator (9 out of 13), while 
about one quarter was initiated by the industry (3 out of 13). In line with this, the majority of the selected 
HRPs was conducted in one site in Switzerland. 3 out of the 13 selected HRPs are international, multi-
centre studies, which implies that these HRPs needed to be submitted to ethical review in other coun-
tries as well. As regards the authorization procedure, 5 out of the 13 selected HRPs required approval 
by Swissmedic. The EC made their first decision about the selected HRPs mainly under the regular 
procedure that requires participation of at least seven EC members and shall ensure expert and inter-
disciplinary assessment of the application for the conduct of an HRP (Art. 5 OrgO-HRA). In this first 
decision, the ECs most often did not approve the HRPs but specified “conditions”. The duration of the 
whole authorization procedure from first submission to final decision varies remarkably, the median 
lies at 90 days. 
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Table 2: Characteristics of the selected HRPs and all approved HRPs in 2016 
  HRPs selected for the present 
analysis (N=13) 
All HRPs approved in 2016 
(N=1381) 
  Number Per cent Number Per cent 
Characteristics of the HRPs     
Ordinance ClinO 8 61.5% 324 23.5% 
 HRO 5 38.5% 1057 76.5% 
Initiated by Investigator 9 69.2% 1192 86.3% 
 Industry 3 23.1% 189 13.7% 
 Other 1 7.7% n. a. n. a. 
Number of sites Monocentric 9 69.2% 1007 72.9% 
 Multicentre Switzerland 1 7.7% 94 6.8% 
 Multicentre international 3 23.1% 280 20.3% 
Research to obtain degree 4 30.8% 558 40.4% 
Characteristics of the process at the authorities     
Authorities  
involved 
EC 8 61.5% 1235 89.4% 
EC and Swissmedic 5 38.5% 146 10.6% 
EC’s first decision  Approved 1 7.7% 222 16.1% 
 Approved, charges 5 38.5% 488 35.3% 
 Not approved, conditions 7 53.8% 667 48.3% 
 Declined or not considered n. a. n. a. 4 0.2% 
EC review proce-
dure* (first deci-
sion) 
Ordinary 7 53.8% 225 16.3% 
Simplified 5 38.5% 1033 74.8% 
Presidential 0 0.0% 123 8.9% 
 Unknown 1 7.7% 0 0.0% 
Duration from first 
submission to EC’s 
final approval  
Median 90  64  
Minimum 20  n. a.  
Maximum 198  n. a.  
Source for information on all HRP approved in 2016: Clinical Trial Unit Basel (2018a: 18, 20, 21, 24, 27, 58). 
* Presidential review procedure was not possible in the selected cases. In relation to first decisions, the presidential review 
procedure may only be used in the case of applications that concern research involving the further use of biological material 
or health-related personal data with informed consent, see Art. 7 OrgO-HRA.  
The selected HRPs cover a wide range of topics in research involving human beings. Regarding the 
field of specialty, the selected HRPs address questions in anaesthesiology, clinical pharmacology and 
toxicology, dental medicine, gynaecology and obstetrics, neurology, otorhinolaryngology, oral and 
maxillofacial surgery, paediatrics, psychiatry, and rheumatology.  
As outlined above, the objective of the selection of the HRPs was not to gain a representative sample of 
all HRPs approved in 2016. Rather, the aim was to capture the diversity of research involving humans 
requiring authorization. In view of the considerable heterogeneity of the HRPs, a larger number should 
have been analysed in detail in order to adequately reflect this diversity. Notwithstanding these limi-
tations, Table 2 also provides the statistics of all approved HRPs in 2016.9 It shows that while the selec-
tion approach led to an overemphasis of HRPs regulated in the ClinO and an underemphasis of HRPs 
in French-speaking Switzerland, the distribution of many main characteristics is fairly adequate. For 
example, the majority of the selected HRPs is monocentric, investigator-initiated and received a first 
decision of “charges” or “conditions”. Furthermore, HRPs mainly conducted to obtain a degree are also 
represented in the present analysis. Based on these considerations, we conclude that our sample is not 
biased to such an extent that the findings could be called into question.  
 
9 The statistics for 2016 only cover HRPs that have been submitted and approved in 2016 because BASEC has only been used by all EC 
as of January 2016. HRPs that have been submitted before 2016 may thus not be included. However, comparing the main statistics 
suggests that the relative numbers do not vary considerably between 2016 and 2017 (Clinical Trial Unit Basel 2018a, 2018b). 
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2.2 Bases: Application dossiers of the HRPs and human research quality criteria 
2.2.1 Documentary basis: electronic dossiers of the applications for authorization of the HRP 
The electronic documentation of the HRPs available at the ECs and, if applicable, Swissmedic is the 
main source for the analysis. Because many documents can be collected during the authorization pro-
cedure and the conduct of an HRP, the analysis focuses on the authorization procedure until first ap-
proval. Two versions of the application dossiers and the corresponding decision letters are of particular 
interest: 
(1) Original submission:  
Dossier of the application that has been submitted for the first time, including the decision letter 
of the authorities regarding this submission. 
(2) First approved submission:10  
Dossier of the application that has been approved without charges, including the decision letter of 
the authorities communicating the approval. 
If the authorities approve the original submission, the two versions are identical. There may also exist 
additional versions of the application dossiers as well as correspondence between the authorities and 
the applicants.11 Consequently, however, the present analysis does not cover documents submitted or 
decisions made during the conduct or at the end of the HRPs. Eventual substantial amendments to an 
HRP that require authorization, e.g. when another trial location is added or the PI changes, are thus not 
object of the investigation. This also applies for reports of events12, annual reports of clinical trials or 
final reports of the HRPs.  
While the specific requirements for the submissions depend on the type and properties of the HRP, the 
electronic documentation usually contains the following documents:13 
- Cover letter 
- Study protocol, incl. a synopsis of the HRP 
- Patient, or more generally, participant information sheet and informed consent 
- CV of the principal investigator (PI) or project leader 
- Information on the nature and value of compensation for participants 
- Information on secure handling and storage of biological material and personal data 
- Decisions of the EC(s), if applicable Swissmedic  
In order to enhance coordination, swissethics provides templates for several documents, namely for 
the study protocol, the participant information sheet and the ECs’ decision letter (see Widmer et al. 
2019a). In 2016, when the applicants submitted the selected HRPs, templates were being revised or only 
being created (swissethics 2016, 2017). This is why we can observe different versions of templates in 
the application dossiers. In multilingual Switzerland, these documents exist in different languages. 
While the study plan and many other documents are often in English, participant information, corre-
spondence with the authorities and the synopsis of the HRP are written in local language, i.e. German, 
French or Italian.  
 
10 We use the term “first approved submission” because approval is also necessary in the later course of an HRP if there is a substantial 
amendment to the HRP.  
11 The PI respectively project leader or the sponsor may submit the application for authorization to the EC (Art. 24 ClinO; Art. 14 HRO). 
Applications for authorization by Swissmedic must be submitted by the sponsor (Art. 31 ClinO).  
12 I.e., serious adverse event (SAE) or suspected unexpected serious adverse reaction (SUSAR) 
13 An overview of the documents to be submitted per study type is provided on swissethics’ website: https://www.swisseth-
ics.ch/BASEC_assets/BASEC_ListOfAllDocuments.pdf [accessed: 11.10.2019]. 
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Because the application dossiers contain very sensitive and confidential information, the authorities 
(EC, Swissmedic) and the researchers’ permissions were needed to access the documentation. Follow-
ing initial contact during spring 2018, we informed the responsible researchers in detail about the anal-
ysis at the end of 2018. On the basis of this detailed information we requested permission14 for us and 
the external specialists to access the application dossiers at the authorities. The present analysis covers 
only HRPs in which the responsible researchers have explicitly consented to the analysis. The authori-
ties were involved throughout this process of information and getting consent and made the electronic 
documentation of the selected HRPs accessible to us. 
2.2.2 Conceptual basis: Human Research Quality Criteria 
A framework of human research quality criteria is used in order to have a meaningful reference for the 
assessment of the quality of the applications submitted and the decisions taken. We have developed 
these human research quality criteria in an iterative procedure. Generally, the criteria rest upon the 
legal bases (HRA and its ordinances, in particular the authorities’ review areas), upon international 
guidelines and standards as well as upon relevant literature concerning quality of research on humans 
(Emanuel et al. 2000, 2008; Raspe et al. 2012; von Niederhäusern et al. 2017). A draft of the human 
research quality criteria was discussed with the advisory group of the evaluation of the HRA. Based on 
their feedback and then-newly published research (Gryaznov et al. 2018; von Niederhäusern et al. 2018), 
we have refined the criteria. The term “quality” and the human research quality criteria are presented 
and discussed in Chapter 3. 
2.3 Procedure: Quality assessment by external specialists, synthesis by evaluation team 
In order to obtain the expertise needed, we have commissioned external specialists to assess the quality 
of the selected HRPs. We commissioned four external specialists to assess the quality of two to four 
HRPs each.15 This proved feasible given the various topics of the selected HRPs and the different lan-
guages of the application documents, but also given the time constraints of the internationally re-
nowned external specialists. To avoid conflicts of interests and to strengthen the independence of the 
assessments as far as possible, only external specialists outside of Switzerland were contacted. All four 
external specialists who have eventually analysed the quality of the selected HRPs are clearly estab-
lished experts in their fields and possess considerable experience in reviewing research involving hu-
mans for the purpose of either systematic reviews or ethics committees. A list of the names and back-
ground information about the external specialists is provided in the Appendix 7.3. For confidentiality 
purposes, no information is provided on who analysed which HRP. 
The external specialists gained access to the electronic documentation with the help of the University 
of Zurich’s service to exchange confidential data. Like us, the external specialists are bound to confi-
dentiality and are only allowed to access the electronic documentation of the selected HRPs for the 
purpose of the analysis. They only had access to the electronic documentation of the HRPs that they 
analysed.16 
 
14 Consent was sought from the sponsor and the PI respectively project leader of the HRP. The number of permissions needed varied 
depending on the set-up of the HRP. 
15 In total, seven external specialists were contacted. 
16 The external specialists were only allowed to access the electronic documentation of the application until first approval. We were also 
allowed to access further information, either via BASEC or via Swissmedic. However, for the purpose of the present report, we only 
accessed information on BASEC to ensure that the application dossiers were complete. For the purpose of the evaluation, we also ac-
cessed BASEC to prepare the interviews with the applicants (see Widmer et al. 2019a: 39-49). 
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To support a systematic assessment and have a meaningful basis for the synthesis, we provided a tem-
plate for the assessment of the individual HRP to the external specialists (see Appendix 7.2). The exter-
nal specialists were specifically asked to explain and justify why they consider a quality criterion (not) 
fulfilled to a certain degree. Because the reports of the external specialists may allow identifying the 
individual selected HRPs, these reports are only for our attention. The external specialists reported 
their results in English or German.  
For the synthesis, we conducted a qualitative content analysis of the specialists’ assessments and, if 
necessary, descriptively analysed the application dossiers to better contextualize the results. On the one 
hand, we compiled and compared the specialists’ assessments. In addition, we examined whether ap-
parent differences exist between HRPs subject to ClinO versus HRO, between international and Swiss-
focused HRPs and between investigator-initiated HRPs and industry trials. On the other hand, we read 
the application dossiers, in particular the synopses of the HRPs and the correspondence with the au-
thorities. We also searched for entries of the HRPs in the Swiss National Clinical Trial Portal (SNTCP) 
and in the international registries of the World Health Organization (WHO) or the U.S. National Li-
brary of Medicine (clinicaltrials.gov).17 As a general rule, reporting of the results needs to be relatively 
abstract in order to prevent identifying any individual HRPs. Feedback of the external specialists on a 
draft version of the synthesis was integrated in the present report. In addition, we clarified a few issues 
with them when drafting the report. 
2.4 Limitations: One qualitative analysis of 13 HRPs submitted two years after HRA enactment 
While our methodological approach aims at providing qualitative statements on the broad area of re-
search involving humans that is subject to the HRA, our methodological approach also comes with 
several limitations. Firstly, the number of HRPs analysed is small. We initially planned to analyse 18 
approved HRPs, but eventually were able to conduct analyses of the quality of 13 approved HRPs. This 
means that we can, at best, draw tentative conclusions about differences in quality depending on the 
HRPs’ characteristics, for example regarding study type. However, as explained above, primary goal 
of the analysis was not representativeness, but to cover the broad range of research involving humans 
subject to the HRA. Moreover, the present analysis was designed as to complement other analyses of 
the quality of research involving humans within the scope of the evaluation of the HRA and govern-
ment research (Gryaznov et al. 2018; Widmer et al. 2019a). 
Secondly, it needs to be taken into account that the HRPs analysed were approved in 2016 or early 2017 
– two years after the HRA came into force. The evaluation has shown that there were initial difficulties 
in implementing the HRA because the necessary processes, structures and activities had not been fully 
in place when the HRA entered into force (Widmer et al. 2019a: 90). When the researchers submitted 
the HRPs analysed, there were many practical yet important changes, in particular regarding templates 
for study protocols or participant information (swissethics 2016, 2017, 2019a, 2019b). These develop-
ments may affect the quality of the HRPs selected and, eventually, the assessments thereof. Further-
more, the evaluation also showed learning processes at the end of the researchers and authorities after 
the enactment of the HRA. However, the present analysis cannot make any statements about the de-
velopment of the HRPs’ quality over time and the role of the HRA therein.  
 
17 We searched for all HRPs in SNCTP by using their BASEC-No. If the entries in SNCTP were not linked to entries in international reg-
istries, we also searched on http://apps.who.int/trialsearch/Default.aspx and https://www.clinicaltrials.gov by using keywords 
from the HRP’s title. 
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Thirdly, it needs to be noted that we can rely on one single assessment per HRP analysed by one of 
four external specialists. This seems necessary for feasibility purposes. While we have asked the exter-
nal specialists to assess the human research quality based on a template, the external specialists still 
have different backgrounds and may have commented or not commented different elements of human 
research quality in their qualitative assessments. This needs to be considered when interpreting and 
discussing the results.  
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3 Conceptual framework: Human research quality criteria 
The quality of research involving human beings is discussed in international guidelines and the Swiss 
legal basis: Helping “to ensure the quality of research involving human beings” is listed as one of the 
HRA’s secondary purposes (Art. 1, para. 2 HRA). However, “human research quality” as such is not 
defined in the legal bases. Several provisions describe the “scientific quality” (see Art. 5 or Art. 10 HRA). 
On the ordinance level, Art. 4 ClinO specifically relates to the “scientific quality”:  
The sponsor and the investigator of a clinical trial shall ensure scientific quality. In particular: 
a.  they shall define a research question based on the current state of scientific knowledge; 
b.  they shall use an appropriate scientific methodology; and 
c.  they shall ensure the availability of the resources required for the clinical trial and provide the necessary 
infrastructure. 
Art. 4 ClinO generally applies to research subject to the HRO as well.18 Next to these provisions related 
to the scientific quality, the term “quality” is also used in the legal provisions regarding the data quality 
and security (see Art. 5 ClinO) and the quality of the therapeutic product used (see, e.g., Art. 32 ClinO). 
Consequently, the elements of human research quality mentioned in the legal bases are part of the 
review areas of the authorities.19 More generally, this implies that the term “human research quality” 
does not solely entail scientific aspects (Rütsche 2015: 98).  
The quality of research involving human beings is also examined in the literature concerning the value 
and ethical conduct of research involving humans. Von Niederhäusern et al. (2017) systematically 
searched conceptions of clinical research quality on websites of governmental bodies, regulatory agen-
cies, the pharmaceutical industry, academic and commercial contract research organisations, initiatives, 
ethics committees, patient organisations and funding agencies. They find that clinical research quality 
is seldom explicitly defined and if, that different stakeholders emphasize different aspects of clinical 
research quality and different stages of research conduct. Therefore, von Niederhäusern et al. (2017) 
conclude that a consensus-based, broad conception of clinical research quality is desirable in order to 
increase the value of clinical research (see von Niederhäusern et al. 2018).20 Such a broad conception of 
human research quality corresponds to the seven respectively eight principles of ethical clinical re-
search according to Emanuel et al. (2000, 2008). As elaborated before, these principles are important 
foundations for the work of the Swiss ECs and beyond (Raspe et al. 2012; swissethics 2013). 
The quality of the selected HRPs was assessed on the basis of the human research quality criteria pre-
sented in Table 3. On the one hand, a total of eight different quality criteria are distinguished. The criteria 
are assigned either to a scientific or an ethical dimension of research involving humans for an easier handling 
and understanding. However, the two dimensions and different criteria rest inherently connected. On 
the other hand, the criteria can be assessed with respect to four aspects of research involving humans: (1) 
the conception and (2) the planned conduct of the HRP, (3) their presentation in the application and (4) 
the decision of the authorities. 
 
18 More specifically, Art. 2 HRO postulates that Art. 4 ClinO applies mutatis mutandis. 
19 In the HRO, “scientific quality” is specifically not mentioned as a review area for HRP involving further use.  
20 Based on their review of definitions of research quality and on online Delphi surveys, von Niederhäusern et al. (2018) have developed 
a framework for research quality called INQUIRE.  
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Table 3: Human research quality criteria 
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Relevance of the  
research ques-
tion 
 Scope of research (research question in the area of research involv-
ing humans; necessity of research involving humans to answer the 
research question) 
 Discussion of relevant previous research (with human- or non-hu-
man subjects) or exploratory analyses 
 Argumentation for relevance of the research question 
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S2 
Suitability of the  
research design 
 Suitability of the design to answer the research question (definition 
and measurement of variables, blinding, population size and rele-
vance, timing of measurements and endpoint, treatment and assign-
ment thereof, statistical method) 
 Pre-defined, standardized approach of collection, documentation 
and quality control of data (incl. anticipation of possible bias) 
S3 
Professional  
qualification 
 Knowledge and experience of the principal investigator/project 
leader with regard to the subject investigated, project management 
and leadership 
S4 
Availability of  
resources and 
responsibilities 
 Planning of necessary resources for the HRP with respect to fi-
nances, personnel, time, rooms, equipment, liability insurance, 
availability of potential participants 
 Clarification of responsibilities 
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E1 
Selection of the  
participants 
 Suitability of inclusion and exclusion criteria to answer the research 
question 
 Fairness of selection (e.g. gender, children, other vulnerable groups, 
healthy volunteers versus patients)  
 Approach of recruiting participants, compensation of participants 
E2 
Information of 
the participants 
 Design of the process of participant information and consent 
 Comprehensibility for laypersons in general and the group of par-
ticipants in particular 
 Comprehensiveness (purpose of research and its procedures prior 
until after the project, potential risks, benefits and alternatives, 
rights and obligations, privacy policy) 
E3 
Protection and 
safety of the  
participants 
 Provisions to minimize risks and burdens and to protect dignity, 
privacy and health of the participants: safety of products or devices 
used, dosage, radiation, protection and privacy measures for han-
dling, access, analysis and storage of data and material (e.g. coding, 
only necessary information collected) 
E4 
Respect for and  
involvement of 
the participants 
 Care during and after the project (handling of adverse or unex-
pected events, contact person, post-trial access to treatment) 
 Respect for participants (possibility of withdrawal, right to know 
and right not to know) 
 Availability of public information 
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The main purpose of this framework of human research quality criteria is to assure a systematic assess-
ment of the relevant aspects to the quality of HRPs. It is intended to be applicable to the different areas 
within research involving humans. Moreover, it is intended to reflect the diverse needs of the different 
stakeholders in research involving humans (researchers, participants, funding bodies and public, au-
thorities) and to cover different phases of the research and authorization process. However, the frame-
work with its eight criteria concerning four aspects shall not be understood as an additive index. Nei-
ther shall the order and abbreviations of the criteria indicate their relative importance. All criteria and 
aspects have an impact on the consideration of an HRP’s risks and burdens relative to its benefit.21  
 
  
 
21 This is also why we decided to not include the risk-benefit-ratio as an individual criterion. 
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4 Results 
As outlined in Chapter 2.1, the external specialists have assessed the quality of total 13 HRPs belonging 
to eight different study types and covering diverse topics. While eight HRPs can be classified as clinical 
trials according to the Swiss regulation, five HRPs concern other research involving humans covered 
by the HRO. The majority of the HRPs analysed is focused on Switzerland, while three HRPs are part 
of international studies. About three quarters of the HRPs analysed were initiated by the investigator, 
the other quarter of the HRPs analysed was initiated by an industry company or a third party. Roughly 
half of the investigator-initiated HRPs received third party funding by the European Union (EU), the 
Swiss National Science Foundation (SNSF) or another institution. Moreover, about half of the investi-
gator-initiated HRPs were principally conducted for obtaining a degree. 
In what follows, the external specialists’ assessments are synthesized and discussed. Firstly, the exter-
nal specialists’ individual assessments of the eight criteria are presented. Secondly, the external spe-
cialists’ overall impression of the quality of the HRPs and the decisions made by the authorities is sum-
marized. Lastly, the present results are discussed in the light of previous government research, the 
evaluation of the HRA and other literature. 
4.1 Individual assessments of the human research quality criteria 
4.1.1 Scientific dimension 
The scientific dimension covers mainly questions about the research design and the resources needed 
to conduct this research. The assessment of this dimension is thus mostly based on the study plan and 
the CV or certificates of the PI or project leader, possibly also on additional information about the fa-
cilities where the HRP is being conducted.  
Generally, we observe that the external specialists comment at length on the relevance of the research 
question (S1) and especially on the suitability of the research design (S2), while assessments of the pro-
fessional qualification (S3) and of the availability of resources and responsibilities (S4) are shorter. Sev-
eral reasons may explain this pattern. On the one hand, S1 and S2 can be conceived as broader in focus 
than S3 and S4. On the other hand, due to their academic background, the external specialists may 
emphasize S1 and S2. Furthermore, while S1 and S2 are mostly assessed on the basis of the detailed 
study plan, S3 and S4 can also be assessed on the basis of staff lists and CVs.  
4.1.1.1 S1 – Relevance of the research question 
Overall, the external specialists find the research question addressed in the HRPs analysed to be rele-
vant and well justified in the light of previous research. In the majority of the 13 HRPs analysed, they 
observe that the research question is relevant as it addresses issues that are important with respect to 
the development of a medicinal product, to a certain disease or population or as it concerns an im-
portant public health issue. Moreover, the external specialists find that the research envisaged adds to 
previous research. In a few cases, however, the external specialists critically discuss whether answering 
the specific research question – while generally relevant – is justified in the light of the previous state 
of research presented in the study plan. In other, few cases, the external specialists question the rele-
vance of the research question. While in one case, the research question is seen as too ambitious and 
unspecific, the external specialist wonders how the research question contributes to shedding light on 
a more general topic in another case.  
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With respect to the HRPs’ characteristics, we can observe that the relevance of the research question is 
critically discussed only for investigator-initiated HRPs covered by the HRO. More specifically, it con-
cerns HRPs involving persons. One possible explanation for this pattern is that such research is more 
oriented towards understanding the functioning of the human body or diseases on a more general level. 
Yet, we can also notice that these investigator-initiated HRPs received funding from foundations. 
Therefore, the applicants already needed to convince peers of the relevance of their research in order 
to obtain a grant. On the contrary, the relevance of the research question is assessed more positively for 
the few international studies and, related to this, industry- or third-party-initiated HRPs and clinical 
trials. 
4.1.1.2 S2 – Suitability of the research design 
The external specialists find the research designs generally suitable in order to answer the research 
questions but often wish to have further information on the (planned) methodological procedures. In 
particular, they miss a detailed specification of outcomes of interest and how they are measured, of 
possible confounders and of the statistical tests used. The planned sample size is mostly estimated to 
be appropriate. The external specialists also specifically mention that monitoring or other measures to 
control data quality are in place with regard to four out of the eight clinical trials analysed.22 In a few 
cases, the external specialists observe that other methods can be expected to yield more solid results 
than the specific method chosen. This largely concerns the two retrospective HRPs based on further 
use of data or material. In a single case, the analysis reveals major concerns about the suitability of the 
research design. It is not only questioned whether the research design allows responding to the research 
question, but important information on the methodological procedure is missing and, if available, 
shows several shortcomings.  
The external specialists take issue with the suitability of the research design for HRPs subject to the 
ClinO as well as to the HRO. As said, they question whether the retrospective analysis in the HRPs 
involving further use represents the most reliable methodological approach. This assessment may be 
partly affected by general attitudes about different research methods. However, regarding both HRPs 
involving further use, the external specialists also indicate that the description of the retrospective anal-
ysis does not provide sufficient information, e.g. regarding the specific variables used and their scales 
as well as the tests applied. Again, the assessment of S2 is very positive for HRPs that were initiated by 
the industry or third parties, while the external specialists only raise concerns in the case of investiga-
tor-initiated HRPs. 
4.1.1.3 S3 – Professional qualification 
For all the HRPs analysed, the external specialists have no or only minor concerns about the qualifica-
tion of the PI or project leaders involved. In some applications, the external specialists could not deduce 
from the CV whether the project leader or the PI possesses all the necessary competencies needed to 
conduct the study, e.g. regarding statistical methods or one of the subfields of inquiry. Moreover, the 
external specialists also indicate that in order to properly assess S3, information is not only needed on 
the PI or the project leader but also on the personnel actually conducting the HRP (physicians, nurses, 
 
22 It seems that not all external specialists paid equal attention to data management and monitoring. Moreover, the requirements re-
garding monitoring depend on the study type and the risks associated with the study. While adequate monitoring by the sponsor is 
required for clinical trials in accordance with GCP (see ClinO Art. 5 para 1; ClinO Annex 1), deviations from this requirement are pos-
sible depending on the risk and type of the trial (see ClinO Art. 5 para 3). For the HRPs subject to HRO, monitoring is only recom-
mended but not required. 
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coordinators, statisticians) and consequently on the division of tasks.23 Given the largely positive and 
rather brief assessment of S3, we cannot observe any considerable differences according to the HRPs’ 
characteristics.  
4.1.1.4 S4 – Availability of resources and responsibilities 
According to the assessments, the available resources and the responsibilities of the parties involved in 
the HRPs are well documented in the application. Only in a few cases, the external specialists find that 
financial or time resources allocated to the HRP have not been sufficiently clarified. Connected to the 
explanations regarding the professional qualification above, the external specialists also sporadically 
miss information about who is responsible for what (see 4.1.1.3). With regard to HRPs initiated by the 
industry, the external specialists state that responsibilities are in line with standard current practices. 
The assessments of this criterion do not vary considerably in general and consequently also between 
HRPs. Still, we can observe that the external specialists indicate a lack of information in the case of 
investigator-initiated HRPs within the area of the HRO. 
4.1.2 Ethical dimension 
The ethical dimension draws the attention to those participating in the HRPs. It covers questions about 
the suitability and fairness of selection as well as the process of recruiting and informing possible par-
ticipants. The provisions to protect the participants and minimize their risks as well as care during and 
after the HRP is also assessed. Consequently, relevant documents are the study plan but also patient or 
participant information sheets and declarations of consent.  
Similar to the scientific dimension, we can observe that the assessments of the selection (E1) and infor-
mation of participants (E2) are more detailed than the assessments of the protection and safety of the 
participants (E3) as well as the respect for and involvement of them (E4). Because participant infor-
mation needs to be written in the local language, it is not always available in the native language of the 
respective external specialist. While the external specialists indicate that they are able to generally eval-
uate the participant information, their ability to specifically assess whether the participant information 
is comprehensive for laypersons is possibly limited.  
4.1.2.1 E1 – Selection of the participants 
In the majority of the HRPs analysed, the external specialists find the criteria for selecting the partici-
pants to be appropriate and suitable to answer the research question at hand. In about half of the HRPs 
analysed, the external specialists indicate that selection criteria are clearly and adequately defined so 
that selection is fair, research involving vulnerable groups is – if applicable – well justified, and provi-
sions to minimize selection bias are in place. In other cases, the external specialists either question the 
generalizability of the HRP’s findings due to strict selection criteria or they miss detailed information 
about the selection criteria. More specifically, information is lacking on how exactly the participants 
are selected and contacted. In one case, the application does not contain explanations on how one of 
the main outcomes of interest can be measured given the participants selected. Only in single cases, we 
interpret the external specialists’ concerns to be considerable. In these cases, the selection criteria seem 
 
23 For all study types the following information is to be submitted to the EC: the PI or the project leader's CV, including evidence of his 
or her knowledge and experience, and a list of the other persons involved in the research project, indicating their responsibilities and 
relevant professional knowledge (see HRO Annex 2, ClinO Annex 3). Our own reading shows that some information on the above-
mentioned points was provided in the HRP analysed. Therefore, the external specialists’ assessments suggest that this information 
was too vague.  
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to be too strictly defined. This not only implies that generalizability from these HRPs is limited but also 
that selection is unfair. For example, in one case, women are excluded but the reason for this is not 
explained in the study plan. 
The rationale of selecting participants and its description seem not to differ between the types of study 
but between the scope of the HRPs. We observe that the study plans of the international HRPs all con-
tain comprehensive and clear information about the selection of participants. On the contrary, the ex-
ternal specialists identify major concerns regarding the selection process in two national HRPs, one in 
the area of the HRO, the other in the area of the ClinO. However, we can also observe that there seems 
to be a trade-off between comprehensive selection of participants – implying higher generalizability – 
and feasibility of the HRP, as HRPs with students as participants illustrate.  
4.1.2.2 E2 – Information of the participants 
Overall, the external specialists find the information issued to the participants adequate and the process 
of seeking informed consent well described. The external specialists also appreciate that information 
leaflets for different groups of participants and their families are provided. In a few cases, the external 
specialists question whether some of the terms used in the participant information is comprehensible 
to laypersons. As mentioned above, we can assume that it was not possible to assess thoroughly the 
language of the participant information for all external specialists. In one case, the external specialist 
wishes that contact information of the sponsor and not only of the PI were available on the participant 
information sheet. According to the Swiss regulations, the participant must receive information about 
the sponsor and main sources of funding for the HRP (see Art. 7 let. h ClinO, Art. 8 let. g HRO). In line 
with this requirement, the current swissethics template for participant information also contains re-
marks on the sponsor and funding of the HRP, but it requires only to indicate the contact details of the 
PI, and possibly his or her collaborators, to ensure care during the HRP.24 
Generally, the external specialists varied barely in their assessment of this criterion and we cannot ob-
serve any differences between the study types; however, a special case with respect to this criterion is 
human research involving further use. Informed consent was not sought in both HRPs involving fur-
ther use analysed, but it was instead issued by the ECs on the authority of Art. 34 HRA.25 In one case, 
the external specialist challenges whether gathering informed consent is not feasible after all. The re-
spective applicant argues that consent cannot be sought because many patients do not speak the local 
language, which would lead to a biased sample. However, the external specialist wonders whether 
informing the patients adequately would not be possible if treating them is. In the other case, the ex-
ternal specialist does not question why the applicant asks to resort to Art. 34 HRA. 
4.1.2.3 E3 – Protection and safety of the participants 
The external specialists assess the quality regarding the protection and safety of the participants largely 
positive. In the majority of the HRPs analysed, they comment that the handling of data is specified and 
appropriate. In one instance, though, the external specialist questions whether the “clinical guidelines 
 
24 Previous versions of the swissethics template were in place when the applications for the analysed HRPs were written. The participant 
information template is generally used by all researchers, while the templates for study protocols are mostly intended for investigator-
initiated HRPs. The current versions of the swissethics template in German, French and Italian are available on the swissethics’ web-
site. For clinical trials see: https://www.swissethics.ch/doc/ab2014/Template_Studieninformation_d.pdf [accessed: 21.10.2019]. 
25 Art. 34 HRA stipulates that “[i]f the requirements for informed consent specified in Articles 32 and 33 are not met, further use may be 
made of biological material or health-related personal data for research purposes in exceptional cases if: a. it is impossible or dispro-
portionately difficult to obtain consent or to provide information on the right to dissent, or this would impose an undue burden on the 
person concerned; b. no documented refusal is available; and c. the interests of research outweigh the interests of the person con-
cerned in deciding on the further use of his or her biological material and data.” 
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for handling patient data”, to which the applicant refers, provide information in sufficient detail to 
warrant comprehensive protection of the data. The external specialists further state that the potential 
risks are detected, discussed and provisions to minimize the risks and to protect the participants are in 
place. For several HRPs, the external specialists relativize also that the HRP only involves minimal to 
barely any risks to its participants. Given that we cannot observe much variation in the assessments of 
this criterion, there are also no differences between the different characteristics of the HRPs. 
4.1.2.4 E4 – Respect for and involvement of the participants 
The external specialists generally raise few criticisms regarding the respect for and involvement of the 
participants. In their assessments of criterion E4, the external specialists most often discuss the availa-
bility of public information about the HRPs, namely publication strategy. From these assessments, we 
can conclude that the study plans rather include information about publications targeted at peers than 
information about the HRP’s results to the attention of the participants. In three cases, the external 
specialists remark that there was no information on publication. However, in two cases, the external 
specialists do not deem this relevant because the respective HRPs are either exploratory studies about 
a medicinal product or quality assurance studies on a medical device. As another element of public 
information, the external specialists sporadically refer to public registration. According to Art. 64 ClinO, 
HRPs are required to be registered in the federal database (SNCTP) and in a primary registry recog-
nized by the WHO or on clinicaltrials.gov. In two cases, the external specialists note that they did not 
find the HRP on clinicaltrials.gov. Since one of these two HRPs is listed in the registry of the WHO, it 
still fulfils the legal provisions. Our own analyses show that all eight analysed HRPs subject to ClinO 
are registered in the SNCTP. However, we could not find two out of the eight HRPs in one of the 
applying international registries. As another aspect of E4, the external specialists further discuss care 
during and after the project. In one case, the external specialists did not find any information on this. 
Lastly, the external specialists highlight in several cases that it is possible for the participants to with-
draw at any moment of the HRP.26 Besides the differences between the HRPs that are due to the regu-
lations ClinO and HRO, we did not observe any differences between the HRPs’ characteristics.  
4.2 Overall assessment of the single HRPs and the authorities’ comments 
4.2.1 Overall impression of the quality of the single HRPs and their applications 
Next to the assessment of individual dimensions, we asked the external specialists to share their overall 
impression. The synthesis of these statements shows that the external specialists mostly have no or only 
minor concerns with respect to the HRP as a whole. These concerns mainly pertain to one or several 
criteria in the scientific dimension. More specifically, the external specialists miss information about the 
(planned) analyses, and they question whether the analyses will yield reliable results. Regarding the 
ethical dimension, the external specialists reiterate in their overall assessments concerns or questions 
about the selection of the participants. Selection criteria are not always comprehensively documented 
or are too strict in the opinion of the external specialists. 
Only in single cases, the external specialists issue considerable concerns, as we understand it, about the 
overall HRP. In one case, the assessment shows that while the HRP’s general topic is of interest and 
appropriate measures to inform and protect the participants are in place, the research question is not 
sufficiently specified, and the methodological framework does not allow giving reliable answers. In 
 
26 In line with Art. 7 para. 2 HRA, our analysis shows that the participant information sheets of all HRPs analysed include the right to 
revoke consent at any time without explaining the reasons for this. 
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another case, the external specialist concludes that the information in the application reveals several 
methodological shortcomings in clinical research and that sufficient quality can possibly only be ob-
tained with considerable help of the authorities and subsequent external monitoring. 
It goes without saying that the assessment of the external specialists clearly depends on whether the 
information provided in the application is clear and comprehensive. Based on the external specialists’ 
comments about the individual dimensions, we can observe that the application documentation of the 
first approved submission is mostly complete and informative. As indicated above, though, the exter-
nal specialists also remark that information is missing. This concerns several aspects of the research 
design and the rationale for selecting the participants. However, it also concerns the qualifications of 
the PI or project leader illustrated in the CV and the overall distribution of the research work.  
4.2.2 Authorities’ decisions 
The authorities explain the results of their assessment of the application in decision letters, which con-
sequently provide the most important information source for the present analysis, although other cor-
respondence between the applicant and the authorities was also available. As stipulated in Table 2, the 
original submissions of the HRPs selected were most often not approved right away but the EC decided 
to set “conditions” for approval for 7 out of 13 HRPs. In 5 out of 13 HRPs, the ECs approved the original 
submission, but listed charges to be fulfilled within 30 days. Only in one case, the EC approved the 
original submission right away with no charges. Swissmedic’s process is different than the authoriza-
tion procedure at the ECs. Swissmedic usually does not ask to resubmit revised full applications but 
rather to append additional information or clarification to the original applications. In all five HRPs 
selected, Swissmedic enquired the sponsor to provide further respectively up-to-date information or to 
correct details indicated in its clinical trial application form. 
Based on our reading of the decision letters, the explanations of the authorities mainly refer to the suit-
ability of the research design, the selection, the information and the protection and safety of participants:  
- Regarding the suitability of the research design (S2), the ECs asked in several cases to provide 
further information about the methodological procedure. In addition, the ECs and Swissmedic 
occasionally requested to improve the Case Report Form (CRF).  
- The comments of the ECs regarding the selection of participants (E1) mostly concern the selection 
criteria, while the ECs had concerns about the compensation of participants or the approach of 
recruiting them only in single cases. The comments further indicate that in several cases, selection 
criteria were not clear to the EC because of contradictory information in the application. Only in a 
few cases, the ECs questioned the rationale for excluding or including certain groups of partici-
pants. 
- The information of the participants (E2) was most often commented by the ECs. The comments 
often concern the comprehensibility of the participant information sheet, in a few cases the ECs 
requested to ensure time for reflection or the participant’s ability to consent on a voluntary basis. 
- In most of the HRPs selected, the ECs and Swissmedic also commented on the protection and 
safety of the participants (E3). In line with their review areas, the ECs’ requests rather focused on 
handling and protecting data, such as using only identifiable information when necessary, while 
the Swissmedic’s requests rather focused on the manufacturing and safety of the products respec-
tively devices used.  
In contrast, the authorities had no requests about the other criteria in the majority of the HRPs selected. 
Therefore, we can observe that the authorities’ reservations rather concentrate on the ethical dimension 
of the human research quality criteria.  
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The external specialists have not assessed the authorities’ decisions with respect to the individual hu-
man research quality criteria but rather provided an account of their overall impression. While these 
accounts seem to be influenced by the external specialist’s individual perspective, all external special-
ists generally find the comments of the ECs and Swissmedic27 comprehensible and well founded. In 
more than half of the HRPs analysed, the external specialists have assessed the decisions only positively. 
One external specialist specifically highlights the efficiency of the ECs’ work. Several external special-
ists describe the comments of the ECs to “make very much sense”, to be “estimable”, “very helpful” or 
“targeted at concrete problems”. In one case, the external specialist also clearly states that Swissmedic 
and the EC have contributed to improving the quality of the HRP analysed and to helping applicants 
with limited expertise in clinical research.  
Regarding the other HRPs analysed, the external specialists have raised criticism on different aspects: 
- Several external specialists point to problems that they have identified in their assessment but that 
were not covered in the ECs’ comments.28 Consequently, they wonder whether the authorities 
could have considered these points as well. This concerns remarks on the selection criteria, the 
research design and the missing informed consent in an HRP involving further use. In this respect, 
one external specialist emphasizes that the ECs’ comments are only focused at details but not at 
pitfalls of the research design that could impede the usefulness of the HRP. In another case, con-
cerning one HRP involving further use, the external specialist wonders whether the EC could not 
have insisted on a more thorough explanation why it is not feasible to ask participants for their 
consent.  
- One external specialist also considers the ECs’ decision procedure and pointed to inconsistencies 
in this respect. In particular, this external specialist questions why a multicentre HRP is being 
approved with charges in two centres and not approved in another centre. The external specialist 
finds the charges mentioned in the decision letter to be more fundamental – and also difficult to 
take care of in 30 days’ time given the international scale of the HRP at hand – than the conditions, 
which the external specialist considers to be formalities.29 Generally, the external specialist notes 
that the members of the EC involved in the decision are not well balanced with regard to gender. 
4.3 Discussion of the results in light of previous studies about the HRA 
How can these results be interpreted in light of the evaluation of the HRA and other research about the 
HRA? Several findings presented above are consistent with the observations made in previous studies 
on the HRA: 
Firstly, the synthesis confirms prior results indicating that protocols of industry-initiated trials are of higher 
quality than protocols of investigator-initiated trials. The synthesis shows that the quality assessments differ 
between industry-initiated or international HRPs and investigator-initiated HRPs. In particular, the 
external specialists have assessed the criteria of the relevance of the research question (S1), the suitabil-
ity of the research design (S2), the availability of the resources and responsibilities (S4) and also the 
selection of participants (E1) more positively for the industry-initiated or international HRPs, while 
 
27 Because Swissmedic was involved in the authorization procedures of 5 out of the 13 HRPs, only few comments are available. 
28 As can be inferred from the explanations above, the external specialists did not always mention concerns that they but not the author-
ities have addressed. In other cases, they found the authorities’ decisions fully appropriate despite their concerns.  
29 In fact, the charges concern amendments requested to the participant information sheet and clarifications requested regarding the 
study protocol, while the conditions concern a missing GCP certificate of the local PI and the definitive version of the contract. While 
the external specialists finds the latter points to consist only of formalities, it can also be questioned why the missing GCP has not been 
remarked during formal check. 
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they miss information or have issued concerns about some of the investigator-initiated HRPs.30 This 
supports the findings of Gryaznov et al. (2018) who analysed total 400 RCT study protocols submitted 
to the Swiss ECs in 2012 and 2016. Gryaznov et al. (2018: 6, 16) find that human research quality in 
terms of adherence to SPIRIT31 criteria improved significantly for investigator-initiated trials between 
2012 and 2016. In contrast, adherence to SPIRIT items of industry-initiated RCT study protocols was 
already at a high level in 2012 and did not change significantly in 2016. This improvement of the quality 
of investigator-initiated RCT study protocols is not Swiss-specific, though. Gryaznov et al. (2018: 20) 
observe a similar pattern for RCT study protocols submitted to ECs in Germany and Canada. Since the 
improvement of the quality of investigator-initiated RCT was more pronounced in Switzerland, Grya-
znov et al. (2018: 24) conclude that the HRA and its implementation activities, namely the templates for 
study protocols, may have contributed to this. 
Secondly, the synthesis supports the overall positive evaluation of the authorities’ work. The external spe-
cialists find the comments of the authorities to be well founded and comprehensible. This matches the 
impressions of the interviewed researchers in the evaluation of the HRA: They find the decisions of the 
ECs and Swissmedic largely comprehensible and well structured (Widmer 2019a: 44, see also von Elm 
and Briel 2019: 25). However, in line with one external specialist, some of the interviewed researchers 
also indicate that the ECs’ comments focus too strongly on details that are not relevant for ethical re-
view (Widmer 2019a: 44-45).  
With respect to the ECs’ work, thirdly, our own reading of the decision letters of the HRPs analysed 
confirm that the ECs pay particular attention to the participant information and thus criterion E2. In the 
evaluation of the HRA, the interviewed members of the ECs also indicated that examining the compre-
hensibility of the participant information is key in the authorization procedure (Widmer et al. 2019a: 
28). Furthermore, the EC members interviewed by De Nardi et al. (2018: 6-8) state that they have the 
impression that researchers do not carefully draft participant information sheets. The evaluation of the 
HRA and government research suggest that researchers also observe that the ECs examine participant 
information very diligently, but the researchers find this helpful (Widmer 2019a: 47; see also von Elm 
and Briel 2019: 26-28).  
Fourthly, related to participant information, the present synthesis also supports the evaluation of the 
HRA’s recommendations to increase transparency of research involving human beings. The assessments of 
criterion E4 on the respect for and involvement of the participants shows that most of the HRPs ana-
lysed comply with the regulations on public registration. However, the external specialists’ assess-
ments also suggest that the explanations on publication strategy in the study protocols focus on 
planned publications for the scientific community rather than for the participants. In the evaluation of 
the HRA, the interviewed authorities state that the transparency about the results of HRPs needs to be 
improved (Widmer et al. 2019a: 37). This view is reinforced by the results of the surveys among organ-
isations representing research participants and among research organisations (Widmer et al. 2019a: 76). 
Based on a survey among Swiss residents, Ehrler and Lebert (2018: 53) likewise state that the Swiss 
 
30 Two reasons may partly explain the differences between investigator-initiated and industry-initiated HRPs: Firstly, the investigator-
initiated HRPs represent not only on applied research but also rather basic research: As outlined in 4.1.1.1, the external specialists had 
concerns about the relevance of the research question (S1) in the case of investigator-initiated HRPs that aim at understanding the 
functioning of the human body or diseases on a more general level. Yet, other investigator-initiated HRPs investigating the effect of 
medical devices or other interventions can be considered as applied research. Secondly, investigator-initiated HRPs may be of lower 
quality because they include HRPs by early career researchers seeking to obtain a degree. Four out of the nine investigator-initiated 
HRPs were conducted primarily to obtain a degree but we cannot observe clear systematic differences, which may also be due to the 
small number of HRPs. 
31 SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT), initiative launched in 2007. The SPIRIT state-
ment including the criteria was published in 2013 after systematic review and consultation of experts (Gryaznov et al. 2018: 8). 
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public wishes to have more information about research involving humans and does not know the in-
formation currently offered.  
At the same time, some findings of the present report also add complementary insights to the evalua-
tion of the HRA and government research: 
In particular, the present report draws our attention to the scientific dimension of human research quality. 
The external specialists relatively more often issue concerns about criteria related to the scientific di-
mension than about criteria related to the ethical dimension of human research quality. In single cases, 
the external specialists thus fear that the selected HRPs may produce what is termed in the literature 
as “waste”32 because the research question is not sufficiently specified, or the research design has flaws. 
The evaluation of the HRA also points to need for improvement of the HRA with respect to ensuring 
the quality of research involving human beings33. However, the external specialists’ more critical view 
of the scientific dimension is somewhat contrary to previous results focusing on the researchers’ per-
spective (Widmer et al. 2019a: 45, von Elm and Briel 2018: 29-31): In surveys and interviews, the re-
searchers questioned whether the ECs possess the relevant expertise to review the HRPs’ relevance and 
research design. The assessments of the external specialists thus imply that the ECs’ concerns regarding 
scientific questions may be well founded. 
There are several reasons why the present report is rather focused on aspects of the scientific than the 
ethical dimension, while the evaluation of the HRA and government research point to the need to im-
prove aspects in the latter dimension, such as participant information and research transparency. One 
explanation may be that the external specialists, due to their background as statisticians or physicians, 
perceived their role in the assessment as scientists and therefore concentrated on the scientific dimen-
sion. Other explanations may be practical: Ethical considerations regarding the protection and infor-
mation of participants may be more difficult to assess without profound knowledge of the legal bases 
in Switzerland. Moreover, participant information was not always available in the native language of 
the external specialist. Another explanation emphasizes the role of the ECs: They have commented on 
the participant information in most cases and thus possibly have contributed to the overall quality of 
these documents that are important for the ethical dimension.  
Lastly, the present analysis shows that the quality of the 13 selected HRPs approved in 2016 and early 
2017 is largely positively assessed but it is not possible to clearly specify to what extent the HRA contributes 
to ensuring and improving the quality of research involving human beings. The evaluation of the HRA and 
government research can neither give an unequivocal answer to this question. The authorities and the 
researchers interviewed find that the quality of the applications has improved since the enactment of 
the HRA. Researchers prepare their submissions and their projects more carefully and are also more 
sensitive towards data protection issues (Frey et al. 2018; Gryaznov et al. 2018; Widmer et al. 2019a). 
However, the authorities interviewed also question the role of the HRA in increasing the quality of 
HRPs. Instead, they mention other important developments targeted at investigator-initiated HRPs, 
such as establishing the Swiss Clinical Trial Organisation (SCTO) and Clinical Trial Units (CTU) or 
activities to train researchers (Widmer et al. 2019a: 37). Moreover, the research organisations’ repre-
sentatives surveyed within the evaluation of the HRA indicate that human research quality has not 
changed as a consequence of introducing the HRA (Widmer et al. 2019a: 74).  
 
32 See, e.g., the series in Lancet 383(9912) about “Research: increasing value, reducing waste”, https://www.thelancet.com/series/re-
search [accessed: 10.11.2019].  
33 In the surveys among research participant organisations and research organisations, the respondents indicate that there is potential to 
improve the HRA with respect to ensuring the quality of human research, however, they fail to clearly identify what needs to be im-
proved (Widmer et al. 2019a: 76-79). 
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5 Conclusion 
Overall, the present analysis shows that the external specialists assess the quality of the 13 selected 
HRPs largely positive. Regarding most of the analysed HRPs, the external specialists have no or only 
minor concerns with respect to one or few criteria. These concerns mostly focus on the relevance of the 
research question, the suitability of the research design and the criteria to select participants. More 
specifically, the external specialists miss information about the (planned) analyses, and they question 
whether the analyses will yield reliable results. They find that selection criteria are not always compre-
hensively documented or that they are too strictly defined. However, the assessments of the individual 
criteria also suggest that, in a few cases, the external specialists miss information about the division of 
tasks within the HRP and in particular about additional staff who supposedly carries out considerable 
parts of the work. Regarding the transparency of research and the involvement of the participants, the 
assessments are diverse and the results less clear, but they seem to indicate that the applications often 
contain information about the publication strategy to the attention of peers but not of participants. Only 
in single cases, the external specialists have considerable concerns about an HRP. These concerns 
mostly relate to major shortcomings in the research design, and partly connected to this, the principal 
investigators’ limited expertise in clinical research.  
Given that 13 HRPs were analysed, we can only make tentative inferences about differences between 
the HRPs. Most likely, we observe that the external specialists assessed the quality of industry-initiated 
or international HRPs more positively than the quality of investigator-initiated HRPs. In submissions 
of the former type, statistical methods, data management, in- and exclusion criteria are discussed in-
depth. This gap between industry- and investigator-initiated HRPs is supported by previous govern-
ment research, in which the completeness and accuracy of RCT study protocols submitted to the seven 
Swiss ECs in 2012 and 2016 was assessed (Gryaznov et al. 2018). This study shows that while the quality 
of study protocols of industry-initiated RCTs remained stable on a high level, the quality of study pro-
tocols of investigator-initiated RCTs significantly improved from 2012 to 2016. However, much of this 
effect seems to be due to an international commitment to enhancing the quality of investigator-initiated 
RCT study protocols than due to the changes in the Swiss regulations (Gryaznov et al. 2018: 20, 24).  
We can observe a few, but no systematic differences for the selected HRPs subject to the HRO and the 
HRPs subject to the ClinO. One notable difference is that the external specialists only had concerns 
about the relevance of the research question for HRPs subject to the HRO. Another difference, which is 
connected to epistemological considerations, concerns the further use of already collected personal 
health-related data or biological material. In their assessments, the external specialists principally ques-
tion whether these retrospective analyses represent the most solid design for establishing inferences. 
Taken together, our results suggest that even though most of the HRPs subject to ClinO required al-
ready approval prior to the HRA, there are no considerable differences between the assessments of the 
quality for studies subject to HRO compared to studies subject to ClinO.  
The present synthesis further confirms the overall positive assessment of the authorities’ decisions and 
their emphasis on matters related to the protection and information of participants. The external spe-
cialists find the authorities’ decisions largely to be comprehensible and well founded. In some cases, 
they also highlight that the authorities have contributed to a learning process of the applicants. Because 
the review areas differ and because only 5 out of the 13 HRP analysed needed approval from Swiss-
medic, the assessments of the authorities’ comments largely focus on the EC. While the external spe-
cialists often describe namely the ECs’ comments as fully appropriate, very helpful or their procedures 
to be efficient, they also raise criticism in some instances. This mostly relates to concerns that the exter-
nal specialists have but which they do not find reflected in the ECs’ comments. More specifically, these 
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concerns pertain to the suitability of the research design, to the selection criteria and, in one case, to 
renouncing from gathering informed consent. In addition to these assessments of the external special-
ists, the analysis of the decision letters shows that the authorities focus in many of their comments on 
the protection of the participants, namely on the comprehensibility of the participant information (ECs) 
and the quality and safety of the product(s) used (Swissmedic).  
The present study thus largely supports results of the evaluation of the HRA and government research, 
but also provides complementary insights into the scientific dimension of human research quality. The 
external specialists expressed still few, but relatively many concerns about criteria of the scientific di-
mension, in particular regarding the relevance of the research question and the suitability of the re-
search design. Concerning the ethical dimension, the external specialists observed pitfalls in selecting 
the participants. Participant information, which clearly needs to be improved according to the evalua-
tion of the HRA and government research on the comprehensibility of participant information, was 
assessed largely positively (De Nardi et al. 2019; Widmer et al. 2019a). One explanation for this empha-
sis on the scientific dimension is that the external specialists with an academic background may have 
focused more on scientific aspects. Another explanation may be that the ECs’ comments have contrib-
uted to the perceived high quality of the participant information. Moreover, as De Nardi et al. (2018, 
2019) argue, it can be assumed that the external specialists, similar to other persons who are regularly 
confronted and therefore familiar with medical jargon, cannot evaluate participant information from a 
layperson’s perspective. 
To conclude, this report presents the synthesis of four external specialists’ qualitative assessments of 
13 selected HRPs, which comes with several limitations. Not only but also for feasibility purposes, the 
analysis is limited to 13 HRPs. This means that it does not cover a large, representative sample of HRPs 
approved in Switzerland and that it allows drawing only tentative conclusions about differences be-
tween the characteristics of HRPs. Given the analysis’ focus on HRPs submitted in 2016, no inferences 
about the improvement of the quality over time can be made. Moreover, the analysis is based on one 
assessment per HRP by an external specialist from outside of Switzerland. The external specialists’ task 
was to assess the quality of the selected HRPs in a qualitative manner by relying on the human research 
quality criteria. This task differs from authorizing HRPs or from analysing the accuracy and complete-
ness of HRPs (Gryaznov et al. 2018). The present analysis thus reveals exploratory findings about the 
quality of research activities within the HRA and complements approaches and findings of the evalu-
ation of the HRA and government research projects. 
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7 Appendix 
7.1 Evaluation of the HRA: Structure, methods employed, and sources used 
Table A 1: Summary of the methods used for the purpose of the evaluation of the HRA 
Module: Subject Survey instruments/data sources 
1. Detailed concept and impact 
model 
 3 informational talks with HR stakeholders 
 Document analysis 
2. Brief description “Stakeholders 
and processes in HR” 
 8 interviews with HR stakeholders 
 Document analysis 
3. HRA implementation from the 
perspective of authorities and 
other stakeholders 
 14 interviews with ECs and federal agencies 
 Synthesis of government research; document analysis 
4. Implementation of the HRA from 
the perspective of researchers 
 31 telephone interviews with applicants (18 regarding authorised applications; 
13 regarding rejected/withdrawn applications) 
 Synthesis of government research 
5. Analysis of research applications 
 Secondary data analysis (including government research) 
 separated: Analysis of the quality of selected research applications34 
6. Effects “Protection/rights of trial 
participants” 
 Standardised online survey of organisations in the area of protection/rights of 
trial participants (N=65 respondents from 51 organisations) 
 Synthesis of government research 
7. Effects “HR quality and frame-
work conditions” 
 Standardised online survey of research organisations (N=189 respondents from 
136 organisations) 
 Synthesis of government research 
8. Context analysis 
 Analysis of data on context gathered from modules 1 to 7 
 Document analysis (including government research) 
9. Synthesis 
 Two regional-language workshops with HR stakeholders on the need for opti-
misation 
 Synthesis of modules 1 to 8, conclusions and recommendations  
Source: See executive summary of the evaluation of the HRA (Widmer et al. 2019b: 4) 
 
 
34 Analysis of selected applications is being carried out separately from the evaluation and is presented in the report at hand. 
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7.2 Template for the assessment of an individual HRP’s quality by the external specialist 
Please use this template for your report on the assessment of the research quality of the human research project indicated below. The template aims at 
supporting a systematic assessment and having a meaningful basis for the comparative synthesis of the assessments of the different human research 
projects. We are aware that it might not be possible to cover all the aspects for all the categories listed and that the relevance of the categories and aspects 
provided might differ within and between the human research projects that you assess. The space needed to elaborate on the assessment of the categories 
might differ as well. Please note that there is additional space provided at the end of the form for any remarks that do not relate to any of the categories 
provided and for the overall impression of the research quality of the human research project. 
Please write your report in English, German or French. Further information about the meaning of the different categories is provided in the annex.  
Project No. [] 
 
Please provide, as far as possible, for each category S1-S4 and E1-E4 an assessment for the following aspects:  
Concept, conduct, application and decision 
 
Does the conception and preparation of the research project ensure the fulfilment of the criteria? 
Do the measures foreseen during the conduct of the project ensure the fulfilment of the criteria? 
Does the application contain the information necessary to assess the criteria? Is the information provided clear and comprehensible? 
Are the decisions well founded, comprehensible and fair? 
Scientific dimension  
S1 
Relevance of the  
research question 
 
S2 
Suitability of the  
research design 
 
S3 
Professional  
qualification 
 
S4 
Availability of  
resources and re-
sponsibilities 
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Project No. [] 
 
Please provide, as far as possible, for each category S1-S4 and E1-E4 an assessment for the following aspects:  
Concept, conduct, application and decision 
 
Does the conception and preparation of the research project ensure the fulfilment of the criteria? 
Do the measures foreseen during the conduct of the project ensure the fulfilment of the criteria? 
Does the application contain the information necessary to assess the criteria? Is the information provided clear and comprehensible? 
Are the decisions well founded, comprehensible and fair? 
Ethical dimension  
E1 
Selection of the  
participants 
 
E2 
Information of the 
participants 
 
E3 
Protection and safety 
of the  
participants 
 
E4 
Respect for and  
involvement of the 
participants 
 
   
Additional remarks 
that do not fit in any of 
the categories provided 
above: 
 
   
Overall impression:  
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Annex: Overview of the human research quality criteria  
    Aspects 
    
C
o
n
ce
p
t 
C
o
n
d
u
ct
 
A
p
p
li
ca
ti
o
n
 
D
e
ci
si
o
n
 
Scientific 
dimension 
S1 
Relevance of the  
research question 
 Scope of research (research question in the area of research involving humans; necessity of research involving 
humans in answering the research question) 
 Discussion of relevant previous research (with human- or non-human subjects) or exploratory analyses 
 Argumentation for relevance of the research question 
D
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 t
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e 
co
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ce
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 p
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 d
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e 
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e 
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n
 c
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 t
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e 
in
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 c
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Is
 t
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e 
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 c
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 c
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A
re
 t
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e 
d
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s 
w
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l-
fo
u
n
d
ed
, c
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b
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 a
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a
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S2 
Suitability of the  
research design 
 Suitability of the design to answer the research question (definition and measurement of variables, blinding, 
population size and relevance, timing of measurements and endpoint, treatment and assignment thereof, sta-
tistical method) 
 Pre-defined, standardized approach of collection, documentation and quality control of data (incl. anticipation 
of possible sources of bias) 
S3 
Professional  
qualification 
 Knowledge and experience of the principal investigator/project leader with regard to the subject investigated, 
project management and leadership 
S4 
Availability of  
resources and re-
sponsibilities 
 Planning of necessary resources for the research project with respect to finances, personnel, time, rooms, equip-
ment, liability insurance, availability of potential participants 
 Clarification of responsibilities 
Ethical  
dimension: 
E1 
Selection of the  
participants 
 Suitability of inclusion and exclusion criteria to answer the research question 
 Fairness of selection (e.g. gender, children, other vulnerable groups, healthy volunteers vs patients)  
 Approach of recruiting participants incl. compensation of participants 
E2 
Information of the 
participants 
 Design of the process of participant information and consent 
 Comprehensibility for laypersons in general and the group of participants in particular 
 Comprehensiveness (purpose of research and its procedures prior until after the project, potential risks, ben-
efits and alternatives, rights and obligations, privacy policy) 
E3 
Protection and 
safety of the  
participants 
 Provisions to minimize risks and burdens and to protect dignity, health and privacy of the participants: safety 
of products or devices used, dosage, radiation, protection and privacy measures for handling, access, analysis 
and storage of data and material (e.g. coding, only necessary information collected) 
E4 
Respect for and  
involvement of the 
participants 
 Care during and after the project (handling of adverse or unexpected events, contact person, post-trial access 
to treatment) 
 Respect for participants (possibility of withdrawal, right to know and right not to know) 
 Availability of public information 
Appendix Analysis of the quality of selected human research projects 
 Evaluation of the Human Research Act 
Page 30 University of Zurich, Department of Political Science and KEK-CDC Consultants, 18 December 2019 
7.3 External specialists 
Table A 2: External specialists: Names, institutional affiliation, functions and fields of expertise  
Name Institution Fields of Expertise 
Name Function Country 
Teresa Anna Cantisani Perugia 
Hospital 
Professor, Director of the Department of 
Neurophysiopathology 
Italy Neurological sciences, sys-
tematic reviews 
Cochrane Head of Cochrane Neurological Sciences 
Field 
 
Josef Haas Medical  
University 
of Graz 
Professor, Department of Obstetrics and 
Gynaecology 
President Ethics Committee 
Austria Biometrics, statistics, medical 
ethics  
Joerg Meerpohl University 
of Freiburg 
Professor, Head of the Institute for Evi-
dence in Medicine 
Germany Epidemiology, paediatric hae-
matology and oncology, sys-
tematic reviews Cochrane Head of Cochrane Germany  
Jürgen Zezula Medical  
University 
of Vienna 
Professor, Institute of Pharmacology 
Co-President Ethics Committee 
Austria Pharmacology, toxicology, 
medical ethics 
 
